Agios Pharmaceuticals Stock News

Harbor Investment Advisory LLC cut its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 83.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 924 shares of the biopharmaceutical companys stock after selling 4,607 shares during the period. Harbor Investment Advisory []

Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective reduced by research analysts at SVB Leerink from $50.00 to $42.00 in a research note issued to investors on Thursday, Analyst Price Targets reports. The firm currently has a market perform rating on the biopharmaceutical companys stock. SVB Leerinks target price would suggest a potential upside of 9.89% []

Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.

Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q3 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the

Comparisons with AGIO are from hundreds of biotech product developers viewed continually by institutional investors as capital gain sources. Values are based on how market professionals protect their

CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetic

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.

The FDA has accepted Agios Pharmaceuticals Inc's (NASDAQ: AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency. Under Priority Review designation, the agen

-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --

Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.

With the trading day nearly halfway over, the broad markets were pulling back into the weekend.

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2021 Results - Earnings Call Transcript

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?